medigraphic.com
ISSN 1729-519X (Print)

2015, Number 6

<< Back Next >>

Revista Habanera de Ciencias Médicas 2015; 14 (6)

Influence of the hemodialysis in the levels of the prostatic specific antigen

Rodríguez CTL, Guzmán CM, Rodríguez BR, Zamora GY

Language: Spanish
References: 18
Page: 774-786
PDF size: 536.00 Kb.


ABSTRACT

Introduction: the symptoms of prostatic diseases are minimum or non-existent, in the patients with chronic renal disease on hemodialysis.
Objective: determine and compare the levels of total, free and free index of prostatic specific antigen in patients under hemodialysis, with conserved renal function patients.
Material and Methods: an observational, descriptive, prospective and comparative study in the Clinical Multiperfil from June to November of 2014 was made. The sample was conformed by 32 patients on hemodialysis and 64 with conserved renal function patients. The variables studied were: age, determination of the total, free and free percentage of the prostatic specific antigen, and hematocrit before and after one low flow membrane hemodialysis session. For the statistical analysis of the data employed the program MEDCAL for Windows version 9. To compare the averages we used the test t student and it was considered a level of significance of p ‹ 0,05.
Results: in both groups main age range was between 56 to 60 years old. The figures of total prostatic specific antigen were similar in both groups (p= 0, 87) before and after hemodialysis (p= 0, 53). The values of the free prostatic specific antigen and his index, went significantly greater in the hemodialysis patients (p ‹ 0, 0001). The hematocrit afterwards of the hemodialysis session was elevated in dialysis group (p= 0,0001).
Conclusions: the values of the free prostatic specific antigen and his index, in Angolans patients with chronic renal disease on hemodialysis, are significantly greater that the ones of patients with conserved renal function, by what are necessary other investigations to rule out the cancer of prostate in these patients.


REFERENCES

  1. Rabinovich J, Klotz T. Multiple synchronous urinary tract tumors in a hemodialysis patient. Urologe A. [Internet]. 2012 Oct; 51 (10): about 3 p. [Cited 2015 Apr 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22695975

  2. Tillou X, Doerfler A. Urological tumors in renal transplantation. Minerva Urol Nefrol. [Internet]. 2014 Mar; 66 (1): about 10 p. [Cited 2015 Apr 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24721941

  3. Hussain S, Abbas, G. Prostate specific antigen levels in pre- dialysis chronic kidney disease patients. Saudi J Kidney Transpl. [Internet]. 2010; 21: about 3 p. [Cited 2015 Apr 14]. Available from: http://www.sjkdt.org/article.asp?issn=1319- 2442;year=2010;volume=21;issue=2;spage=354;epage=356;aulast=Hussain

  4. Bruun L, Savage C, Cronin AM, Hugosson J, Lija H, Christensson A. Increase in percent free prostate- specific antigen in men with chronic kidney disease. Nephrol Dial Transplant. [Internet]. 2009; 24 (4): about 4 p. [Cited 2015 Apr 14].Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721427/

  5. Wolff JM, Ting O, Borchers H, Rohde D, Jakse G. Serum levels of prostate specific antigen in men on hemodialysis. Anticancer Res. [Internet]. 2000; 20 (6D): about 3 p. [Cited 2015 Apr 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11326693

  6. Tzanakis I, Kazoulis S, Girousis N., Kagia S, Spandidakis V, Karefillakis N. et al. Prostate- specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron.[Internet]. 2002; 90 (2): about 4 p. [Cited 2015 Apr 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11818714

  7. Rebbeck TR, Devesa, SS, Chang, BL, Bunker, CH, Cheng, I, Cooney K, et al. Global patterns of prostate cancer incidence, agggressiveness, and mortality in men of african descent. Prostate cancer. [Internet]. 2013; about 12 p. [Cited 2015 Apr 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23476788

  8. Thompson IM, Tangen CM. Prostate cancer – uncertainty and a way forward. NEJM. [Internet]. 2012; 367 (3): about 2 p. [Cited 2015 Apr 14]. Available from: http://www.drkney.com/pdfs/prostateB_0712.pdf

  9. Mustafa M, Ali-el –Dein B. Effect of hemodialysis on total, free and percent- free prostate – specific antigen. Afric J Urol. [Internet]. 2008; 12 (2): about 4 p. [Cited 2015 Apr 14]. Available from: http://www.ajol.info/index.php/aju/article/view/8146

  10. Bruun L, Savage C, Cronin AM, Hugosson J, Lija H, Christensson A. Increase in percent free prostate- specific antigen in men with chronic kidney disease. Nephrol Dial Transplant. [Internet]. 2009; 24 (4): about 4 p. [Cited 2015 Apr 10]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721427/

  11. García Sánchez C, Corchuelo Maíllo C, Román Martín A, Congregado Ruiz C, Osmán García I, Conde Sánchez JM, et al. Niveles de PSA de los pacientes en hemodiálisis. LXXVII Congreso Nacional de Urología. Vigo. [Internet].2012.[Citado 14 Abr 2015]. Disponible en: http://www.aeu.es/aeu_webs/aeu2012/pdfSesiones.aspx?Sesion=54

  12. Maoujoud O, El Machtani S, Asseraji M, Atbib Y, Zajjari Y, Taoufik A, et al. Serum tumor markers in hemodialysis patients. Int J Artif Organs. [Internet]. 2014 Feb; 37 (2): about 7 p. [Cited 2015 Apr 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24619900

  13. Bruun L, Björk T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent- free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant. [Internet]. 2003; 18: about 5 p. [Cited 2015 Apr 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12584285

  14. Mercadal L. Tumor markers in chronic kidney disease. Nephrol Ther. [Internet]. 2015 Apr; 11 (2): about 3 p. [Cited 2015 Apr 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25709104

  15. Fischer K, Hamza A, Wicht A, Loertzer H, Fornara P. Shift of the f/t- PSA quotient in relation to renal insufficiency: Consequences for early detection of propstate carcinoma in patients with terminal renal failure. Anticancer Research. [Internet]. 2007; 27: about 4 p. [Cited 2015 Apr 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17649801

  16. Park JS, Hwa JS, Chung KH. The effect of dialisis on serum prostate specific antigen levels in patients with chronic renal failure. Korean J Urol. [Internet]. 2001; 42 (7): about 4 p. [Cited 2015 Apr 10]. Available from: http://www.koreamed.org/SearchBasic.php?RID=1020KJU%2F2001.42.7.728&DT=1

  17. Mahdavi R, Zeraati A, Tavakkoli M, Aghmohammadpour K, Ghoreifi A. Effect of kidney transplantation on early and late post- transplant prostate-specific antigen levels. Saudi Kidney Dis Transpl. [Internet]. 2014; 25 (2): about 5 p [Cited 2015 Apr 14]. Available from: http://www.sjkdt.org/article.asp?issn=1319- 2442;year=2014;volume=25;issue=2;spage=362;epage=366;aulast=Mahdavi

  18. Sumura M, Yokogi H, Beppu M, Honda H. Diagnostic value of serum prostate – specific antigen in hemodialysis patients. Int J Urol. [Internet]. 2003; 10: about 4 p. [Cited 2015 Apr 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12694463




2020     |     www.medigraphic.com